Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. cancer drug
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Cancer Drug Articles & Analysis

134 news found

CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

These molecules can bind to targets highly expressed on cancer cell surfaces and be targeted during drug delivery. For example, folic acid (folates) can be used. ...

ByCD Bioparticles


Alfa Chemistry Expands Pharmaceutical Product Portfolio: Introducing PROTAC Building Blocks, Nucleosides, Intermediates, and APIs

Alfa Chemistry Expands Pharmaceutical Product Portfolio: Introducing PROTAC Building Blocks, Nucleosides, Intermediates, and APIs

In medical applications, they’re used in cancer therapies and viral infection drugs. Alfa Chemistry makes this possible by providing pure and highly diverse nucleosides with modified versions used in the development of oligonucleotide therapeutics. ...

ByAlfa Chemistry


Tethis S.p.A. Collaborates with Weill Cornell Medicine to Advance Cellular Residual Disease Monitoring in Early-Stage Breast Cancer

Tethis S.p.A. Collaborates with Weill Cornell Medicine to Advance Cellular Residual Disease Monitoring in Early-Stage Breast Cancer

Massimo Cristofanilli, a Professor of Medicine at Weill Cornell Medicine, and at Tethis, will focus on patients with early-stage breast cancer who are given drugs to reduce tumor size, prior to surgery to remove the tumors. ...

ByTethis S.p.A


SOPHiA Genetics and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

SOPHiA Genetics and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized version of the highly validated liquid biopsy test developed by Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution. ...

BySOPHiA Genetics


Amerigo Scientific Enhances Cell Culture Results by Introducing 3D Cell Culture Systems

Amerigo Scientific Enhances Cell Culture Results by Introducing 3D Cell Culture Systems

To date, 3D cell culture systems, including scaffold-based and scaffold-free, have been widely applied in differentiation studies, drug discovery, cancer research, gene and protein expression studies, and cellular physiological studies. ...

ByAmerigo Scientific


Alfa Cytology Launches Full-Scale Preclinical Services for Pancreatic Cancer Research   

Alfa Cytology Launches Full-Scale Preclinical Services for Pancreatic Cancer Research  

Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. ...

ByAlfa Cytology


CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence

CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence

This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug discovery, cancer research, and tissue engineering. The Centre of Excellence will house state-of-the-art CELLINK bioprinters, including the flagship BIO X6 and BIONOVA X bioprinters, a range of bioinks and the leading ...

ByCELLINK


Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes

Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes

Working with patient-derived biopsies, immune cells and cancer stem cells to develop 3D bioprinted Micro-Tumors, Carcinotech has been providing the pharmaceutical sector with crucial services in assisting researchers to optimize drug testing workflows. ...

ByCELLINK


CD ComputaBio Unveils Cutting-Edge Advances in Antibody Drug Design and Development

CD ComputaBio Unveils Cutting-Edge Advances in Antibody Drug Design and Development

Prominent within the field of computational biology, CD ComputaBio, unveils its cutting-edge Antibody Drug Design Services and Antibody Development solutions. Driven by an unwavering commitment to advancing precision medicine, the company stands at the forefront of redefining therapeutic strategies and expediting drug discovery processes, fostering innovation ...

ByCD ComputaBio


CD Bioparticles Announces New PLGA-Based Drug Delivery Systems for In Vitro and In Vivo Applications

CD Bioparticles Announces New PLGA-Based Drug Delivery Systems for In Vitro and In Vivo Applications

In recent years, the development of nanotechnology has had a tremendous impact on the development of novel nano-drug delivery systems. Various organic or inorganic materials have been used to prepare nano-drug delivery systems for safe and effective cancer therapy. PLGA-based drug delivery systems have attracted great interest ...

ByCD Bioparticles


Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be presented Bayer ...

ByBayer AG


Lynx Bio Makes Headway on New Diagnostic for Blood Cancer Drugs

Lynx Bio Makes Headway on New Diagnostic for Blood Cancer Drugs

In 2009, as a graduate student at the University of Wisconsin-Madison, Chorom Pak was part of a group of researchers working to understand how sensitive patients’ cells were to certain therapies for blood cancers, such as multiple myeloma. The group, which also included UW-Madison professors Shigeki Miyamoto and David Beebe, and postdoctoral fellow Edmond Young, would receive ...

ByLynx Biosciences, Inc.


BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring

BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring

BioMark intends to use this funding to support research and development of a quantitative assay to measure drug metabolites for cancer treatment monitoring. The project is leveraging the fully integrated BioMark’s metabolomic liquid biopsy platform to develop a safe, effective, and affordable drug biomarker test to assess and monitor ...

ByBioMark Diagnostics Inc.


Stilla and Promega Announce Co-Marketing Agreement to Offer Complete Digital PCR Workflow Solution

Stilla and Promega Announce Co-Marketing Agreement to Offer Complete Digital PCR Workflow Solution

With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. Representative data of the liquid biopsy workflow will be presented at the American Association for Cancer Research (AACR) ...

ByStilla Technologies


Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets

Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets

The Cellworks platform uses computational biosimulation to model signaling pathways, master regulators, hallmark behaviors of cancer, and drug interactions with each patient’s unique disease network. ...

ByCellworks Research India Private Limited


xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study

xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study

The end goals are to determine whether this targeted method of delivering chemotherapy can extend survival while also improving quality of life. Although pancreatic cancer treatment has improved, pancreatic cancer patients continue to have poor outcomes – partially due to the tissue surrounding the tumor hampering intravenously delivered chemotherapy ...

ByxCures


LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

(Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional and accredited investors for $5.8 million of common stock. ...

ByLIXTE Biotechnology Holdings, Inc.


Christer Nordstedt resigns as acting CEO of Vivesto

Christer Nordstedt resigns as acting CEO of Vivesto

” About Vivesto AB Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients ...

ByVivesto AB


Creative Proteomics Metabolomics Unveils Drug-Resistant Metabolomics Research Service

Creative Proteomics Metabolomics Unveils Drug-Resistant Metabolomics Research Service

Drug therapy is one of the major modalities for cancer treatment. However, drug resistance may reveal whether it is chemotherapy drugs, targeted drugs, or immunotherapy drugs. Once drug resistance (especially multidrug resistance) is developed, cancer ...

ByCreative Proteomics


Vivesto announces that Christer Nordstedt will remain as acting CEO during a transition period

Vivesto announces that Christer Nordstedt will remain as acting CEO during a transition period

About Vivesto AB Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a ...

ByVivesto AB

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT